Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|Tubular Breast Cancer Stage III|HER-2 Positive Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: background treatment
Sponsor: German Breast Group
Collaborators: Teva Pharmaceuticals USA|Roche Pharma AG|GlaxoSmithKline